Cytokinetics Incorporated (CYTK) - News Archive

Cytokinetics Grants Inducement Options and Units to CFO Sung H. LeeSOUTH SAN FRANCISCO, Calif., June 04, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) has recently announced the granting of stock options, restricted...

SOUTH SAN FRANCISCO, Calif., May 28, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company, is excited to announce the successful completion of its underwritten public offering of common...

Cytokinetics Incorporated, a leading biopharmaceutical company based in South San Francisco, announced the successful pricing of a public offering of their common stock. The offering includes 9,803,922 shares, priced at...

SOUTH SAN FRANCISCO, Calif., May 22, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) recently announced its plans for an underwritten public offering of approximately $500 million worth of shares of its common stock. H...

In a significant move to support the commercial launch of their groundbreaking drug, Aficamten, and bolster their research and development (R&D) pipeline, Cytokinetics, a leading biopharmaceutical company, has announced...

Cytokinetics, a leading biopharmaceutical company, recently presented the primary results of the SEQUOIA-HCM clinical trial at the European Society of Cardiology Heart Failure 2024 Congress. The results, which were also...

Cytokinetics, Incorporated, a pioneer in the biopharmaceutical industry, has recently announced that its CEDAR-HCM (Clinical Evaluation of Dosing with aficamten to Reduce Obstruction in a Pediatric Population in HCM) cl...

SOUTH SAN FRANCISCO, Calif., May 02, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) recently released news regarding the granting of stock options and restricted stock units (RSUs) to five new employees as a material...

Cytokinetics, a pre-eminent bio-pharmaceutical enterprise focusing on muscle biology and related diseases, has recently announced three late-breaking clinical trial presentations that shed light on the outcomes of the S...

:Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the heart muscle, leading to impaired cardiac function and a range of clinical symptoms. Current treatment options...

Cytokinetics Incorporated Grants Stock Options to New Employees Amidst Declining Share PriceIn a recent press release, Cytokinetics, Incorporated announced that it has granted stock options to purchase an aggregate of 7...

Cytokinetics, Incorporated, a biopharmaceutical company, recently announced its partnership with the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) in support...

In a groundbreaking partnership, Cytokinetics, The Mended Hearts, Inc., and WomenHeart have joined forces to launch a revolutionary initiative aimed at increasing engagement in cardiovascular clinical trials. Recognizin...

Cytokinetics, the renowned pharmaceutical company, has announced the recipients of its Sixth Annual Communications Grant Program. In a noteworthy philanthropic step, a total of $100,000 has been awarded to five chosen p...

Cytokinetics, a leading biopharmaceutical company specializing in the development of novel therapies for cardiovascular and neuromuscular diseases, recently presented new data at CMR 2024 regarding the clinical trial of...

:Obstructive hypertrophic cardiomyopathy (HCM) is a complex and potentially life-threatening cardiac disorder affecting a significant proportion of the global population. In recent years, there has been a growing need t...

IntroductionIn a recent press release, Cytokinetics, a leading biopharmaceutical company, unveiled the results from its renowned clinical trial, COURAGE-ALS, at the 34th International Symposium on ALS/MND. The highly an...